Shaanxi Micot Technology Co., Ltd. was established in 2007, which is a high-tech company professionally engaged in preclinical and clinical research of new drugs. The company is located in Xi’an Hi-tech Industries Development Zone, and the R＆D and pilot scale production base is located in Fengdong New Town in Xixian New Area with building area of 3500㎡ and equipped with international advanced instruments and equipments. The company is found by the returned students. 70% personnel in the technical team have doctorate and overseas study experience, containing the fields of pharmacy, pharmacology, toxicology, clinical research, biometry, iatrology, registration and declaration, etc.

The company owns exclusive technological resources: 1. a global advanced innovative platform combinative with chemical drug screening technology and biomedical research technology to discover completely innovative synthesis which are leading in the world; 2. the first key technology and product R＆D platform of biomacromolecule respiratory tract delivery system “Bio-Res-Deliv” in the world; 3. a national-level platform for key slow-release technology and product R＆D of polypeptide and protein biological drugs (State approval No.: 2013ZX09509106). The company is mainly engaged in the product R＆D of the innovative chemical drugs for cardiovascular diseases, metabolic diseases and hepatic diseases, the innovative biological drugs of polypeptide and protein, and vaccines and biomolecule drug delivery system. At present, the company is researching over ten types of new drugs in Category 1, of which, there are two types of products have acquired the clinic approval for new drugs from SFDA and another two are in the process to apply to the approval of new drugs from American FDA (including other countries and regions).

The company has established the Industry - Education – Research Cooperation with several pharmaceutical groups, quoted companies, transnational pharmaceutical companies and university, such as Buchang Pharma, the quoted company Er-Kang Pharmaceutical Co., Ltd., China National Biotec Group Company Limited, Novartis Tianyuan Pharmaceutical Co., Ltd. and Xi'an Jiaotong University through a series of integrated new type of cooperation and management models, like resource sharing, mutual matching and mutual support, devoting itself to innovation of new drugs and improvement of health for long term and researching and developing the salvage and therapeutic drugs for the front line in order to improve people's life quality, server people’s health and realize self-worth.